Generic Drugs Program Monthly and Quarterly Activities Report

ACTIONS BY MONTH	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Apr-26	May-26	Jun-26	Jul-26	Aug-26	Sep-26	FY-2026
Approvals	54	58	46	59	64	56	85	42					464
First-Time Generics	5	6	6	6	6	7	41	6					83
First-Cycle Approvals	15	6	7	17	18	17	10	11					101
Imminent Actions	11	8	4	13	13	4	25	2					80
Tentative Approvals	21	26	23	19	26	31	19	21					186
First-Cycle Tentative Approvals	2	6	5	5	4	4	1	8					35
Imminent Actions	7	12	6	4	5	10	3	5					52
Complete Responses	98	92	88	124	90	80	84	77					733
Original ANDAs Refuse-to-Receive	1	2	1	2	2	2	0	0					10
Standard	0	2	1	2	1	1	0	0					7
Priority	1	0	0	0	1	1	0	0					3
Original Acknowledgements	55	51	24	64	62	40	53	86					435
Withdrawals	84	10	13	27	5	16	26	14					195
Approved ANDAs	72	3	0	20	0	9	18	0					122
Unapproved ANDAs	12	7	13	7	5	7	8	14					73
PAS Approvals	114	122	158	138	142	150	124	116					1064
PAS Refuse-to-Receives	1	0	0	0	0	0	1	0					2
PAS Withdrawals	7	13	16	18	9	10	15	14					102
Information Requests	494	473	495	414	373	410	387	425					3471
Originals	266	178	232	208	228	221	199	246					1778
Supplements	228	295	263	206	145	189	188	179					1693
Discipline Review Letters	172	119	107	154	165	274	101	184					1276
DMF Completeness Assessments	53	52	20	31	27	39	39	45					306
Reclassifications of a Facility-Based Major CRL Granted	11	3	11	8	3	10	12	6					64
Reclassifications of a Facility-Based Major CRL Denied	0	0	2	0	0	0	0	1					3
Pending ANDAs Awaiting FDA Action +	1300	1272	1326	1265	1233	1277	1300	1316					--
ANDAs Awaiting Applicant Action ++	1880	1871	1845	1872	1861	1833	1783	1770					--
Tentative Approvals +++	575	585	585	581	584	585	561	566					--
Complete Responses ++++	1305	1286	1260	1291	1277	1248	1222	1204					--

 

SUBMISSIONS BY MONTH	Oct-25	Nov-25	Dec-25	Jan-26	Feb-26	Mar-26	Apr-26	May-26	Jun-26	Jul-26	Aug-26	Sep-26	FY-2026
ANDAs *	1	46	95	32	28	107	49	58					416
Complex Products	0	8	19	12	5	26	10	39					119
Amendments	161	198	184	168	161	184	198	138					1392
Major	52	60	56	46	62	56	67	46					445
Minor	50	48	60	65	54	70	74	47					468
Unsolicited	59	90	68	57	45	58	57	45					479
Requests for Reclassification of a Facility-Based Major CRL Amendment	5	19	4	1	8	16	10	9					72
Pre-Submission Facility Correspondences	3	2	3	3	3	3	3	3					23
Supplements	875	768	922	933	868	981	1189	948					7484
CBEs	727	639	717	813	742	858	1020	806					6322
PASs **	148	129	205	120	126	123	169	142					1162
DMF Payments	0	23	29	22	17	30	27	15					163
Controlled Correspondence ***	263	234	361	267	362	359	362	321					2529
Level 1	214	198	306	232	305	320	326	270					2171
Level 2	49	36	55	35	57	39	36	51					358
Controlled Correspondence Requests for Clarification	1	0	0	1	1	1	1	7					12
Product Development Meeting	8	3	6	6	6	8	5	8					50
Pre-Submission Meetings	2	0	2	0	0	1	0	1					6
PSG Teleconferences	0	1	0	0	0	1	0	0					2
Pre-Submission PSG Meetings	0	0	0	0	0	0	0	0					0
Post-Submission PSG Meetings	0	0	0	0	0	0	0	0					0
Mid Cycle Review Meetings	0	0	0	0	0	0	0	0					0
Enhanced Mid Cycle Review Meetings	0	0	0	0	0	0	0	1					1
Post-CRL Clarification-Only Teleconference	7	4	5	5	5	4	4	3					37
Post-CRL Scientific Meeting	1	0	2	2	1	0	0	2					8

 

APPROVAL TIMES BY QUARTER ^	Q1 (Oct - Dec)	Q2 (Jan- Mar)	Q3 (Apr - Jun)	Q4 (Jul - Sept)
Quarterly Mean Approval Times	35.93	32.82
Quarterly Median Approval Times	25.65	20.29
Quarterly Mean Tentative Approval Times	45.83	49.74
Quarterly Median Tentative Approval Times	32.15	33.79

Note

Numbers reflect current data at the time of posting and may change based on refreshed counts in our tracking systems, including application status updates. These numbers are not intended for Congressional reporting purposes. Indented metrics are included in the count of the non-indented metric above it.

Abbreviations

PAS = Prior Approval Supplements
DMF = Drug Master File
CRL = Complete Response Letter
CBE = Changes Being Effected
PSG = Product-Specific Guidances

+ = Pending ANDAs Awaiting FDA Action are applications currently being reviewed by FDA.
++ = ANDAs Awaiting FDA Action and ANDAs Awaiting Applicant Action represent a snapshot in time for the status of distinct original ANDAs. Many of these applications have been reviewed and found “not approvable” in a previous cycle and have been resubmitted by the applicant for another cycle of review and assessment. These metrics are calculated at the end of the month or just thereafter.
+++ = ANDAs Awaiting Applicant TA are applications that have a status of ‘TA’ or Tentative Approval. If a generic drug product is ready for approval but cannot be approved due to a patent or exclusivity related to the reference listed drug product, FDA issues a tentative approval letter to the applicant, and the tentative approval letter details the basis for the tentative approval. A tentative approval does not allow the applicant to market the generic drug product. The Federal Food, Drug, and Cosmetic Act (FD&C Act) delays final approval of the generic drug product until all patent or exclusivity issues have been resolved or, in some cases, until a 30-month stay associated with patent litigation has expired.
++++ = Applications Awaiting Applicant Action are applications that have a status of ‘CR’ or Complete Response. These applications have been reviewed by FDA and the data submitted are inadequate to support approval.

* = Original Receipts are reported as raw receipts (versus filed receipts).
** = PAS Supplements do not include REMS PAS supplements.
*** = Controls count only those requests deemed appropriate for a control.

^ = Mean/ Median AP/TA calculated as the difference between the first full approval (AP) date or the first Tentative Approval (TA) date and the date the original application was accepted for filing divided by the average number of days per month (30.4375). The unit for each of these metrics is months.

Previous Monthly Reports

• Activities Report of the Generic Drug Program (FY 2025)
• Activities Report of the Generic Drug Program (FY 2024)
• Activities Report of the Generic Drug Program (FY 2023)
• Activities Report of the Generic Drug Program (FY 2022)
• Activities Report of the Generic Drug Program (FY 2021)
• Activities Report of the Generic Drug Program (FY 2020)
• Activities Report of the Generic Drug Program (FY 2019)
• Activities Report of the Generic Drug Program (FY 2018)
• Activities Report of the Generic Drug Program (FY 2017)
• Activities Report of the Generic Drug Program (FY 2016)
• Activities Report of the Generic Drug Program (FY 2015)
• Activities Report of the Generic Drug Program (FY 2014)
• Activities Report of the Generic Drug Program (FY 2013)

Previous Quarterly Reports

• FY 2022 | GDUFA II Quarterly Performance
• FY 2021 | GDUFA II Quarterly Performance
• FY 2020 | GDUFA II Quarterly Performance
• FY 2019 | GDUFA II Quarterly Performance
• FY 2018 | GDUFA II Quarterly Performance